SYNCOMF2024-04-012024-06-30 SYNCOMF2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member SYNCOMF2024-06-30 SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue01Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue02Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentRevenue03Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults01Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults02Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentResults03Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets01Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets02Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentAssets03Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2024-06-30in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2024-06-30in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2024-06-30in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524470 SYNCOMF NOTLISTED Syncom Formulations (India) Limited Equity 2024-04-01 2025-03-31 2024-08-12 2024-08-02 INR Lakhs First quarter 16:00:00 16:30:00 2024-08-12 2024-08-12 Not applicable Multi segment 2024-04-01 2024-06-30 Unaudited Consolidated 872554000.00 13384000.00 885938000.00 530313000.00 42861000.00 -28040000.00 96492000.00 3903000.00 13000000.00 126388000.00 784917000.00 101021000.00 0.00 101021000.00 24390000.00 306000.00 24696000.00 0.00 76325000.00 0.00 0.00 0.00 0.00 76325000.00 27593000.00 103918000.00 0.00 0.00 0.00 0.00 940000000.00 1 0.11 0.11 0.00 0.00 0.11 0.11 0.00 0.00 0.00 OTHER EXPENSES 126388000.00 Pharmaceuticals Drugs & Formulations 863031000.00 Renting of Property 9666000.00 Trading of Commodities 13241000.00 885938000.00 0.00 885938000.00 Pharmaceuticals Drugs & Formulations 95625000.00 Renting of Property 8859000.00 Trading of Commodities 439000.00 104923000.00 3903000.00 0.00 Notes:- 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/08/2024. 2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as Ind AS ) as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time. 3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required. 4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been conducted for the quarter ended on 30th June, 2024. The report does not have any impact on the above results and notes which needs explanation. 5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 101020000.00 Pharmaceuticals Drugs & Formulations 2984925000.00 Renting of Property 473345000.00 Trading of Commodities 96442000.00 3554712000.00 Pharmaceuticals Drugs & Formulations 524186000.00 Renting of Property 18132000.00 Trading of Commodities 16745000.00 559063000.00 0.00 559063000.00 0.00 ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS 27593000.00 27593000.00 0.00